Complete CMV diagnostics to improve patient outcomes:

1. Early Detection of CMV Reactivation, Primary Infections
2. Monitor Response to Treatment
3. Confirm Antiviral Resistance
4. Establish Immunity 

Benefits of working with Eurofins Viracor:

  • Industry leading turnaround time for all of our CMV Assays

  • Assay refinement using dual targets, multiple probes and mutation surveillance ensures your patient will be evaluated using the most up-to-date and accurate testing

  • Ability to send all of your CMV testing to one lab:
  • Multiple specimen types accepted for ease of collection

CMV Testing for Transplant & Immunocompromised Patients

 

  Test Name Test Code Turnaround Time & Test Details  
PCR /
Viral Load		 CMV Real-time Quantitative PCR

5500
  • Same day (within 8-12 hours from receipt of specimen)
  • Most specimen types offer quantitative results
  • Over 19 specimen types
CMV Saliva Real-time PCR

5571
  • Same day (within 8-12 hours from receipt of specimen)
  • Saliva samples are simple, noninvasive, and easy to collect for congenital CMV detection
  • Sample collection within 21 days after baby is born to confirm diagnosis

 

Resistance

NEW
CMV Resistance: Maribavir, Letermovir, Ganciclovir, Foscarnet, Cidofovir

33125
  • Within 2-4 days of receipt of specimen (often reported in just 2.5 days)
  • Plasma specimen type
  • DNA viral load must be above 1000 uL/mL to run—one of the lowest minimum viral loads in the industry

NEW
CMV Resistance: Maribavir, Ganciclovir, Foscarnet, Cidofovir

33126

CMV Resistance: Letermovir

30722
Immunity CMV inSIGHT™ T Cell Immunity Panel 30360
  • 2-3 days from receipt of specimen
  • Whole Blood in sodium heparin
  • Live Cell tests have special collection and shipping requirements

Innovations in CMV Immunity

CMV inSIGHT™ T Cell Immunity Assay

  • Assess current immune response for viral target
  • Confirm if virus specific CD4 and CD8 T Cells are present
  • Evaluate treatment decisions

CMV inSIGHT logo

CMV T Cell Immunity Test

WHITE PAPER

Evaluating Cytomegalovirus Cell Mediated Immunity Diagnostic Assays

Optimizing CMV Outcomes

Viracor can make it easier for healthcare providers to manage CMV patients with testing options spanning the continuum of care.

Baseline & Monitor Viral Load

Quantitative CMV PCR can be used for early detection of reactivation, primary infection and monitoring response to treatment.

Dual gene targets and multiple probes increases the assay’s ability to pick up polymorphisms, therefore reducing the chance for false negatives and detecting other strains that could otherwise be missed.

Learn More

Confirm Antiviral Resistance

Patient outcomes depend on effective prophylaxis and treatment with antiviral therapies, including ganciclovir, valganciclovir, foscarnet, cidofovir, letermovir, and maribavir. 

Laboratory testing should be used to confirm drug resistance, as treatment modification based solely on clinical suspicion may result in added toxicity and increased complexity in patient management.

Learn More

Establish Immunity

The CMV T Cell Immunity Panel measures the strength of T cell responses to CMV-specific antigens and reports the activity of CD4 and CD8 T cell responses independently. 

Evaluating immunocompromised patients’ CMV-specific T cell response will help healthcare providers decide when to take patients off of antiviral medication during critical stages in treatment.

Learn More

Watch how Viracor's CMV T Cell Immunity Panel Helps A Post-Transplant CMV Treatment Plan

Discover how Eurofins Viracor is revolutionizing the field of diagnostic testing in our CMV video. We showcase our cutting-edge technologies and innovative approaches that enhance patient care and improve clinical outcomes. Learn about our commitment to accuracy, reliability, and personalized medicine through our comprehensive testing services and how your patient's immune system reacts to CMV medication. Join us in exploring how our expertise is transforming diagnostics to better serve healthcare providers and their patients.

 

References

1 Kotton CN, Kumar D, Caliendo AM, et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation. Apr 15 2010;89(7):779-95.

2 Boeckh M, Ljungman P. How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood. 2009;113(23):5711-9.

Chat With An Expert

Back to top